Spatial multi-omics in targeted cancer immunotherapies

Immune checkpoint inhibitors have emerged as an effective treatment for various cancer types. Anti-PD-1/PD-L1 immune checkpoint inhibitor therapy provides a durable effect when given to patients likely to respond, however, identifying these patients remains a challenge. Therefore, focusing on developing a consistently predictive biomarker to guide patient selection for highly targeted checkpoint inhibitor therapies is key.

In this webinar, Dr. Arutha Kulasinghe, NHMRC Research Fellow and Clinical-oMx Group Leader at the Frazer Institute, University of Queensland, will discuss how single-cell multiomic spatial phenotyping is an invaluable tool to characterize the tumor microenvironment using unbiased whole-slide imaging of metastatic/recurrent HNSCC tumors among patients treated with pembrolizumab/nivolumab. He will also explain how using these techniques, his team were able to identify stromal, immune, and metabolic tissue signatures associated with resistance to immunotherapy and poor overall survival.

Key learning objectives

• Understand spatial biology approaches
• Learn how to profile deep tumor microenvironments
• Understand how to decode immunotherapy responses
• Discover applications for skin, lung and head, and neck cancer

Who should attend?

• Researchers
• Principal investigators
• Professors
• Post-doctoral researchers

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.